Alkylphosphocholine-induced glioma cell death is BCL-XL-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation

Cell Death and Differentiation

Volumn 11, Issue 12, 2004, Pages 1326-1341

  Naumann, Ulrike ^a   Wischhusen, J ^a   Weit, S ^a   Rieger, J ^a   Wolburg, H ^b   Massing, U ^c   Weller, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Alkylphosphocholines; Apoptosis; BCL XL; Glioma; Vacuoles

Indexed keywords

1 O PHOSPHOCHOLIN 2 ACETYLOCTADECANE; 1 O PHOSPHOCHOLIN 2 O METHYLOCTADECANE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 7; CASPASE INHIBITOR; CYTOCHROME C; CYTOKINE RESPONSE MODIFIER A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL XL; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; ASTROCYTE; CELL IMMORTALIZATION; CELL STRUCTURE; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME RELEASE; GENE TRANSFER; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; PREDICTION; PRIORITY JOURNAL; PROTEIN PROCESSING; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTES; BCL-X PROTEIN; BRAIN NEOPLASMS; CASPASES; CELL LINE, TUMOR; COLLAGEN TYPE XI; CYTOPLASM; FREE RADICALS; GLIOMA; HUMANS; MEMBRANE POTENTIALS; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; PHOSPHORYLCHOLINE; POLY(ADP-RIBOSE) POLYMERASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STEARATES; VACUOLES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 9944257505     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401503     Document Type: Article

References (41)

1. Glioma Meta-Analysis Trial Group. (2002) Chemotherapy in adult high-grade glioma: a systematic review and a meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018
2. Weller M and Thomas DGT (2003) Primary tumors of the central and peripheral nervous system In Course and Treatment of Neurological Disorders, Brandt T, Caplan LR, Dichgans J, Diener HC and Kennard C (ads) San Diego, CA, USA: Academic Press, pp. 827-863
3. Muschiol C, Berger MR, Schuler B, Scherf HR, Garzon FT, Zeller WJ, Unger C, Eibl HJ and Schmahl D (1987) Alkyl phosphocholines: toxicity and anticancer properties. Lipids 22: 930-934
4. Berdel WE (1991) Membrane-interactive lipids as experimental anticancer drugs. Br. J. Cancer 64: 208-211
5. Jendrossek V, Hammersen K, Erdlenbruch B, Kugler W, Krugener R, Eibl H and Lakomek M (2002) Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother. Pharmacol. 50: 71-79
6. Matzke A, Massing U and Krug HF (2001) Killing tumour cells by alkylphosphocholines: evidence for involvement of CD95. Eur. J. Cell Biol. 80: 1-10
7. Triggiani M, Goldman DW and Chilton FH (1991) Biological effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in the human neutrophil. Biochim. Biophys. Acta 1084: 41-47
8. Kleuser B, Meister A, Sternfeld L and Gercken G (1996) Measurement of phospholipase A2 and 1-alkylglycerophosphocholine acetyltransferase activities in stimulated alveolar macrophages by HPLC analysis of NBD-labeled ether lipids. Chem. Phys. Lipids 79: 29-37
9. Unger C and Eibl H (1986) In Mammakarzinome, Nagel GA (ed) Berlin: Springer Verlag, pp. 115-123
10. Verdonck LF, Witteveen EO, van Heugten HG, Rozemuller E and Rijksen G (1990) Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid. Cancer Res. 50: 4020-4025
11. Hoffmann DR, Hoffmann LH and Snyder F (1986) Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. Cancer Res. 46: 5803-5809
12. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H and Lakomek M (1999) Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother. Pharmacol. 44: 484-490
13. Massing U and Eibl H (1994) Synthesis of enantiomerically pure 1-O-phosphocholine-2-O-acyl-octadecane and 1-O phosphocholine-2-N-acyl-octadecane. Chem. Phys. Lipids 69: 105-120
14. Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H and Weller M (2001) CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20: 4128-4137
15. Squier MK, Miller AC, Malkinson AM and Cohen JJ (1994) Calpain activation in apoptosis. J. Cell. Physiol. 159: 229-237
16. Sedarous M, Keramaris E, O'Hare M, Melloni E, Slack RS, Elce JS, Greer PA and Park DS (2003) Calpains mediate p53 activation and neuronal death evoked by DNA damage. J. Biol. Chem. 278: 26031-26038
17. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M and Hanada K (1982) L-trans Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201: 189-198
18. Horn M, Pavlik M, Doleckova L, Baudys M and Mares M (2000) Arginine-based structures are specific inhibitors of cathepsin C. Application of peptide combinatorial libraries. Eur. J. Biochem. 267: 3330-3336
19. Wagenknecht B, Glaser T, Naumann U, Kügler S, Isenmann S, Bähr M, Korneluk R, Liston P and Weller M (1999) Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 6: 370-376
20. Naumann U, Durka S and Weller M (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17: 1567-1575
21. Glaser T, Wagenknecht B, Groscurth P, Krammer PH and Weller M (1999) Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene 18: 5044-5053
22. Glaser T and Weller M (2001) Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. Biochem. Biophys. Res. Commun. 281: 322-327
23. Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP and Weller M (2002) BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J. Neurooncol. 56: 43-49
24. Lockshin RA and Zakeri Z (2002) Caspase-independent cell deaths. Curr. Opin. Cell Biol. 14: 727-733
25. Gozuacik D and Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906
26. Jendrossek V, Müller I, Eibl H and Belka C (2003) Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 22: 2621-2631
27. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM and Strasser A (2002) Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 419: 634-637
28. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A and Dichgans J (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer 79: 640-644
29. Puthalakath H and Strasser A (2002) Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9: 505-512
30. Yi X, Yin XM and Dong Z (2003) Inhibition of Bid-induced apoptosis by Bcl-2. tBid insertion, Bax translocation, and Bax/Bak oligomerization suppressed. J. Biol. Chem. 278: 16992-16999
31. Sander M, Trump BF, Harris CC and Tennant RW (2003) Seventeenth Aspen Cancer Conference: mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy. Mol. Carcinogenesis 36: 101-114
32. Cardenas-Aguayo Mdel C, Santa-Olalla J, Baizabal JM, Salgado LM and Covarrubias L (2003) Growth factor deprivation induces an alternative non-apoptotic death mechanism that is inhibited by Bcl2 in cells derived from neural precursor cells. J. Hematother. Stem Cell Res. 12: 735-748
33. Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M and Weller M (2001) Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res. 61: 5833-5842
34. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH and Fontana A (1995) Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25: 2253-2258
35. Naumann U and Weller M (1998) Retroviral BAX gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. Int. J. Cancer 77: 645-648
36. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC and Van Meir EG (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9: 469-479
37. Winkelmeir P (1993) Quantification of cytotoxicity by cell volume and cell proliferation. Alternatives Lab. Anim. 21: 269-280
38. Leist M, Single B, Naumann H, Fava E, Simon B, Kuhnle S and Nicotera P (1999) Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp. Cell. Res. 249: 396-403
39. Steinbach JP, Wolburg H, Klumpp A, Probst H and Weller M (2003) Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ. 10: 823-832
40. Cossarizza A, Baccarani-Contri M, Kalashnikova G and Franceschi C (1993) A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′ -tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 197: 40-45
41. Reber U, Wüllner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, Dichgans J and Weller M (1998) Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. Biochem. Pharmacol. 55: 349-359